In 2019 NICE is due to commence the review of this guidance, to register as a stakeholder please contact us at medtech@nice.org.uk

NICE has developed medical technology guidance on the transurethral resection in saline (TURis) system.

NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

NICE has said that the TURis system can be used instead of a surgical system called ‘monopolar transurethral resection of the prostate’ (or monopolar TURP).

Healthcare teams may want to use the TURis system instead of monopolar TURP because:

  • there is no risk of a rare complication called transurethral resection syndrome and
  • it is less likely that a blood transfusion after surgery will be needed.

Compared with monopolar TURP, the TURis system can save money depending on the equipment a hospital currently uses.

Using the TURis system may shorten the time spent in hospital after prostate surgery. It may also reduce the chances of the man having to go into hospital again because of complications from the surgery. The savings are greater if these factors are taken into account.

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)